Metastatic Castration-resistant Prostate Cancer Clinical Trials in Myrtle Beach, South Carolina
14 recruitingMyrtle Beach, South Carolina
Showing 1–14 of 14 trials
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Hoffmann-La Roche100 enrolled32 locationsNCT07287150
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Metastatic Castration-resistant Prostate Cancer
AstraZeneca670 enrolled90 locationsNCT07611110
Recruiting
Phase 2
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Kyntra Bio75 enrolled20 locationsNCT06842498
Recruiting
Phase 1
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo60 enrolled19 locationsNCT07244341
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.218 enrolled33 locationsNCT07005154
Recruiting
Phase 1
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited67 enrolled8 locationsNCT06801236
Recruiting
Phase 1
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)+2 more
K36 Therapeutics, Inc.144 enrolled13 locationsNCT07103018
Recruiting
Phase 1Phase 2
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Metastatic Castration-resistant Prostate Cancer
Merck Sharp & Dohme LLC1,200 enrolled21 locationsNCT02861573
Recruiting
Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.174 enrolled25 locationsNCT04729114
Recruiting
Phase 2
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Dendreon400 enrolled31 locationsNCT06134232